Express Healthcare
Home  »  News  » receives global recognition for OCPAP at ASCO annual meeting receives global recognition for OCPAP at ASCO annual meeting

0 357
Read Article

Concordance study comparing treatment guidance provided by OCPAP platform against that provided by panel of senior oncologists was found to provide right treatment guidance to patients with high accuracy recently received global recognition for its advanced technology platform ‘Online Cancer Patient Assistance Pathway’ (OCPAP) at the recently held annual meeting of the American Society of Clinical Oncology (ASCO) in May 2020. A concordance study comparing the treatment guidance provided by the OCPAP platform against that provided by a panel of senior oncologists was found to provide the right treatment guidance to patients with very high accuracy. The study was presented by Dr Amit Jotwani, Co-Founder and Chief Medical Officer,

As per the Global Survey of Clinical Oncology Workforce 2018, for every 10,000 cancer patients, there are only 1-5 trained oncologists in developing countries like India. Scarcity of oncologists and lack of accessibility to healthcare are key factors that contribute to the high mortality-incidence ratio of 0.68. In light of these staggering statistics,’s concordance study opens up a new possibility of affordable and accessible cancer guidance that could transform the healthcare landscape globally. Integration of the algorithm with care management tools is being assessed in a bid to further improve treatment compliance and outcomes.

According to Dr Jotwani, “We studied the accuracy of the guidance provided by this platform by comparing its guidance with that provided by a panel of senior oncologists for 448 cases studied. In this study, we found that OCPAP could provide accurate treatment guidance for 93 per cent of patients and this accuracy was consistent across cancer types and different stages of disease. The lowest concordance was recorded at 74 per cent for brain tumours where there is substantive subjectivity among doctors owing to clinical findings and tumour characteristics noted on scans. More than 50,000 users have already used this platform to date and we continue to serve hundreds of patients on a daily basis through OCPAP.”

According to Rashie Jain, CEO and Co-Founder,, “At Onco, we are excited about building technology-aided solutions that can improve cancer care delivery globally. Being recognised at ASCO for our OCPAP platform is a significant milestone for us. The platform has allowed us to provide guidance to thousands of cancer patients free of cost – something we are all very proud of. We are looking forward to building many more tech solutions in the future.”

Leave A Reply

Your email address will not be published.

Attend an exclusive webinar to know more about biomarkers in diagnosis & therapy management of heart failure.
Register Now
 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?
Are you looking for ICP-MS which can increase productivity and remove time trap from your analysis?
Know More